marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-12-2024
Clearside Biomedical Balance Sheet 2011-2024 | CLSD
Annual Balance Sheet Clearside Biomedical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-27.9 M | -47 M | -29.8 M | - | -16.2 M | 34.2 M | 24 M | 21.6 M | -14.3 M | -8.27 M | -1.64 M | - | - |
Long Term Debt |
649 K | 936 K | 288 K | - | 3.82 M | 9.42 M | 4.81 M | 7.59 M | 4.24 M | - | 268 K | - | - |
Long Term Debt Current |
364 K | 349 K | 387 K | 373 K | 360 K | 556 K | 3.2 M | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 4.72 M | 10 M | 5.56 M | 7.75 M | 52.5 M | 27.1 M | 12.2 M | - | - |
Total Current Liabilities |
6.81 M | 5.78 M | 4.64 M | 9.94 M | 10.9 M | 10.5 M | 13.5 M | 5.41 M | - | - | - | - | - |
Total Liabilities |
49.9 M | 40.7 M | 4.93 M | 10.6 M | 15.6 M | 20.5 M | 19.1 M | 13.2 M | 57.7 M | 29.5 M | 12.9 M | - | - |
Deferred Revenue |
75 K | 205 K | - | 5 M | 5 M | - | - | - | - | - | - | - | - |
Retained Earnings |
-321 M | -288 M | -255 M | -256 M | -238 M | -207 M | -124 M | -65.2 M | -39.4 M | -21.7 M | -11.5 M | - | - |
Total Assets |
34 M | 51.3 M | 42.9 M | 19.3 M | 26.8 M | 44.1 M | 40.5 M | 84.8 M | 21.1 M | 10.3 M | 2.14 M | - | - |
Cash and Cash Equivalents |
28.9 M | 48.3 M | 30.4 M | 17.3 M | 22.6 M | 8.04 M | 9.22 M | 34.8 M | 20.3 M | 8.27 M | - | - | - |
Book Value |
-15.9 M | 10.6 M | 38 M | 8.76 M | 11.2 M | 23.6 M | 21.4 M | 71.7 M | -36.7 M | -19.2 M | -10.7 M | - | - |
Total Shareholders Equity |
-15.9 M | 10.6 M | 38 M | 8.76 M | 11.2 M | 23.6 M | 21.4 M | 71.7 M | -36.7 M | -19.2 M | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Clearside Biomedical
| 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
412 K | 493 K | 649 K | 724 K | 796 K | 867 K | 936 K | - | 105 K | 200 K | 288 K | 374 K | 458 K | 539 K | 616 K | 385 K | 496 K | 616 K | 3.82 M | 3.82 M | 3.82 M | 3.82 M | 9.42 M | 9.42 M | 9.42 M | 9.42 M | 4.81 M | 4.81 M | 4.81 M | 4.81 M | 7.59 M | 7.59 M | 7.59 M | 7.59 M | 4.24 M | 4.24 M | 4.24 M | 4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
64 M | 62.2 M | 49.9 M | 47.3 M | 44.2 M | 42 M | 40.7 M | 37.1 M | 5.5 M | 4.36 M | 4.93 M | 9.53 M | 9.25 M | 10.8 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 15.6 M | 15.6 M | 15.6 M | 15.6 M | 20.5 M | 20.5 M | 20.5 M | 20.5 M | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 13.2 M | 13.2 M | 13.2 M | 13.2 M | 10.4 M | 10.4 M | 10.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | 225 K | 75 K | - | 355 K | 280 K | 205 K | 113 K | - | 198 K | - | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | - | - | - | - | - | - | - | - | - | - | 20 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-348 M | -340 M | -321 M | -316 M | -307 M | -298 M | -288 M | -279 M | -271 M | -263 M | -255 M | -274 M | -269 M | -263 M | -256 M | -256 M | -256 M | -256 M | -238 M | -238 M | -238 M | -238 M | -207 M | -207 M | -207 M | -207 M | -124 M | -124 M | -124 M | -124 M | -65.2 M | -65.2 M | -65.2 M | -65.2 M | -39.4 M | -39.4 M | -39.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
29.2 M | 33.9 M | 34 M | 34.4 M | 39.2 M | 44.7 M | 51.3 M | 55.7 M | 30.7 M | 36.1 M | 42.9 M | 27.4 M | 28.6 M | 27.8 M | 19.3 M | 19.3 M | 19.3 M | 19.3 M | 26.8 M | 26.8 M | 26.8 M | 26.8 M | 44.1 M | 44.1 M | 44.1 M | 44.1 M | 40.5 M | 40.5 M | 40.5 M | 40.5 M | 84.8 M | 84.8 M | 84.8 M | 84.8 M | 21.1 M | 21.1 M | 21.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
13.9 M | 18.2 M | 28.9 M | 28.8 M | 35 M | 41.4 M | 48.3 M | 53.4 M | 29 M | 34.4 M | 30.4 M | 25.2 M | 26.4 M | 26.1 M | 17.3 M | 17.3 M | 17.3 M | 17.3 M | 22.6 M | 22.6 M | 22.6 M | 22.6 M | 8.04 M | 8.04 M | 8.04 M | 8.04 M | 9.22 M | 9.22 M | 9.22 M | 9.22 M | 34.8 M | 34.8 M | 34.8 M | 34.8 M | 20.3 M | 20.3 M | 20.3 M | - | 8.27 M | - | - | - | 1.91 M | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
-34.8 M | -28.3 M | -15.9 M | -12.8 M | -4.97 M | 2.7 M | 10.6 M | 18.5 M | 25.2 M | 31.7 M | 38 M | 17.8 M | 19.3 M | 17 M | 8.76 M | 8.76 M | 8.76 M | 8.76 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 23.6 M | 23.6 M | 23.6 M | 23.6 M | 21.4 M | 21.4 M | 21.4 M | 21.4 M | 71.7 M | 71.7 M | 71.7 M | 71.7 M | 10.7 M | 10.7 M | 10.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-34.8 M | -28.3 M | -15.9 M | -12.8 M | -4.97 M | 2.7 M | 10.6 M | 18.5 M | 25.2 M | 31.7 M | 38 M | 17.8 M | 19.3 M | 17 M | 8.76 M | 8.76 M | 8.76 M | 8.76 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 23.6 M | 23.6 M | 23.6 M | 23.6 M | 21.4 M | 21.4 M | 21.4 M | 21.4 M | 71.7 M | 71.7 M | 71.7 M | 71.7 M | -36.7 M | -36.7 M | -36.7 M | - | -19.2 M | - | - | - | -10.7 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency